Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

GenomSys is proud to announce the successful finalization of the series A investment round.

GenomSys, a software company which develops ISO compliant technology for efficient processing and sharing of DNA data, announced it has completed its series A investment round. The company raised CHF 9.3 million in this financing, driven by the accelerating development progress of its MPEG-G-based solution for DNA data processing.

The Series A round was led by Preon Capital, the Geneva-based family office of Jari Ovaskainen, Europe’s 2014 Business Angel of the year. Preon was joined by a group of European and U.S. investors, including the Club degli Investitori – the most active business angel network in Italy , the Elysia Capital and Pygar family offices, linked respectively to the founder of the European unicorn Advanced Accelerator Applications and to the multinational diagnostic company Diasorin. U.S.-based investors Dolby Family Ventures and Susman Ventures participated in this financing. Pascal Levensohn, Managing Director of these funds, has joined the GenomSys board of directors.

Founded in 2016, GenomSys has developed technology facilitating access to highly-secured personalized medicine services. Its product portfolio includes solutions to compress, browse, store and share genomic information based on the model of digital media compression and streaming technology.  Decreasing costs of genomic sequencing are enabling DNA analysis to become mainstream, promising wider accessibility for medical professionals to generate new perspectives.  GenomSys’ solutions solve the associated challenges from the ever-increasing data volumes, format proliferation, storage costs and analytic complexity caused by this data explosion.

Based on the newly released ISO MPEG-G Standard, GenomSys’ Software Suite “will bring a dramatic reduction in genomic files’ size, a faster information transfer and more efficient data analysis”, says Claudio Alberti, GenomSys’ co-founder.

As stated by the International Organization for Standardization (ISO), MPEG-G “provides the enabling technology that will allow the community to create an ecosystem of novel, interoperable, solutions in the field of genomic information processing”. MPEG-G will also bring genomic information to personal devices, which will accelerate individuals’ access to personalized medicine, while enforcing strict data-privacy standards.

Schedule a call

[contact-form-7 id="224" title="contact call"]